Skip to main content

Table 2 Characteristics of the trials eligible for meta-analysis

From: Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis

Article (Jadad score) Design Number of patients Delivery method Type of surfactant Surfactant dosing (total) Treatment duration Number of deaths Ventilation-free daysa Duration of ventilationb
        Control Surfactant   Control   Surfactant   Control   Surfactant
Weg and colleagues, 1994 [16] (score 5) Multicenter: USA, Canada 51 (control = 17, group 1 = 17, group 2 = 17) Aerosolized Exosurf (synthetic, no surfactant protein) 13.5 mg DPPC/ml (group 1, 21.9 mg DPPC/kg/day; Group 2, 43.5 mg DPPC/kg/day) Maximum 120 hours for all groups 8 Group 1 = 7, group 2 = 6 NA NA NA NA
Anzueto and colleagues, 1996 [17] (score 5) Multicenter: USA, Spain, France 725 (control = 361, surfactant = 364) Aerosolized Exosurf (synthetic, no surfactant protein) 13.5 mg DPPC/ml (112 mg DPPC/kg/day) Maximum 5 days 143 145 NA NA 16.4 (0.9) 16.0 (1.0)
Gregory and colleagues, 1997 [18] (score 2) Multicenter: USA 59 (control = 16, group 1 = 8, group 2 = 16, group 3 = 19) Intratracheal Survanta bovine lung extract (containing SP-B and SP-C) Group 1, 50 mg/kg LBW (maximum 8 doses); group 2, 100 mg/kg LBW (maximum 4 doses); group 3, 100 mg/kg LBW (maximum 8 doses) Maximum 96 hours for all groups 7 Group 1 = 4, group 2 = 3, group 3 = 3 NA NA 10 Group 1 = 15c, group 2 = 7c, group 3 = 10c
Spragg and colleagues, 2003 [19] (score 2) Multicenter: USA, Canada 40 (control= 13, group 1 = 15, group 2 = 12) Intratracheal Venticute (rSP-C-based surfactant) Group 1, 1 mg/kg LBW (maximum 4 doses); group 2, 0.5 ml/kg LBW (maximum 4 doses) 24 hours for all groups 5 Group 1 = 3, group 2 = 4 6 (0–15) Group 1= 5 (0–18), group 2 = 4 (0–12) NA NA
Spragg and colleagues, 2004 [20] (score 4) Multicenter: Europe, South Africa 227 (control = 109, surfactant = 118) Intratracheal rSP-C-based surfactant 1 mg/kg LBW (maximum 4 doses) 24 hours 43 46 0 (0–20) 0 (0–19) NA NA
Spragg and colleagues, 2004 [20] (score 4) Multicenter: USA, Canada 221 (control = 115, surfactant = 106) Intratracheal rSP-C-based surfactant 1 mg/kg LBW (maximum 4 doses) 24 hours 29 34 6 (0–21) 3.5 (0–21) NA NA
  1. DPPC, dipalmitoylphosphatidylcholine; LBW, lean body weight; rSP-C, recombinant surfactant protein C; NA, not available.
  2. aValues presented as median (25th–75th percentile).
  3. bValues presented as mean (± standard deviation).
  4. cValues presented as median.